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Background: Stemona tuberosa has long been used in Korean and Chinese medicine to ameliorate various lung
diseases such as pneumonia and bronchitis. However, it has not yet been proven that Stemona tuberosa has
positive effects on lung inflammation.
Methods: Stemona tuberosa extract (ST) was orally administered to C57BL/6 mice 2 hr before exposure to CS for
2 weeks. Twenty-four hours after the last CS exposure, mice were sacrificed to investigate the changes in the
expression of cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), chemokines such as
keratinocyte-derived chemokine (KC) and inflammatory cells such as macrophages, neutrophils, and lymphocytes
from bronchoalveolar lavage fluid (BALF). Furthermore, we compared the effect of ST on lung tissue morphology
between the fresh air, CS exposure, and ST treatment groups.
Results: ST significantly decreased the numbers of total cells, macrophages, neutrophils, and lymphocytes in the
BALF of mice that were exposed to CS. Additionally, ST reduced the levels of cytokines (TNF-α, IL-6) and the tested
chemokine (KC) in BALF, as measured by enzyme-linked immunosorbent assay (ELISA). We also estimated the mean
alveolar airspace (MAA) via morphometric analysis of lung tissues stained with hematoxylin and eosin (H&E). We
found that ST inhibited the alveolar airspace enlargement induced by CS exposure. Furthermore, we observed that
the lung tissues of mice treated with ST showed ameliorated epithelial hyperplasia of the bronchioles compared
with those of mice exposed only to CS.
Conclusions: These results indicate that Stemona tuberosa has significant effects on lung inflammation in a subacute
CS-induced mouse model. According to these outcomes, Stemona tuberosa may represent a novel therapeutic herb for
the treatment of lung diseases including COPD.
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Cigarette smoke (CS) comprises more than 4,500 com-
pounds, including human carcinogens and many toxins
such as nicotine, carbon monoxide [1]. CS, which is one
of the risk factors of chronic obstructive pulmonary dis-
ease (COPD), increases various respiratory symptoms
resulting from functional lung abnormalities such as a* Correspondence: hbae@khu.ac.kr
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CS induces lung inflammation through different types
of mechanisms, including reduced fibroblast prolifera-
tion and migration, and genetic mutations in the lung
[3-6]. Furthermore, various types of inflammatory cells,
cytokines and chemokines are widely studied with re-
gard to the activation of acute or chronic inflammation
in the lungs, which may be important factors for under-
standing the mechanisms of lung inflammation and devel-
oping new approaches to treat lung diseases including
COPD [7].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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sis factor-alpha (TNF-α) and interleukin-6 (IL-6) and the
chemokine, keratinocyte-derived chemokine (KC) which
is a neutrophil chemoattractant, were found to be ele-
vated in the bronchoalveolar lavage fluid (BALF) of mice
[8]. Inflammatory cells including macrophages, neutro-
phils, and lymphocytes also accumulated in BALF. These
inflammatory cells release inflammatory substances such
as enzymes that destroy collagen and elastin and stimu-
late mucosal secretions in the lung tissues, resulting in
lung diseases like emphysema, chronic bronchitis, and
COPD [1].
Meanwhile, COPD is a major public health problem
worldwide. By definition, COPD is characterized by con-
tinued airflow limitation that is progressive and is associ-
ated with an increasing chronic inflammatory response
in the airways and the lung to hazardous particles or
gases, including CS. COPD has a higher risk of mortality
than other diseases such as angina, respiratory infection,
fractures, myocardial infarction, and osteoporosis [9]. In
2020, COPD is expected to rank fifth in terms of the
burden of disease and will likely rank third as a cause of
mortality [10].
Roflumilast, a common therapy for lung diseases such
as asthma and COPD, has been shown to inhibit the
increased secretion of cytokines such as TNF- α and
interferon-gamma (INF-γ), and chemokines such as
CCL2, CCL4, CXCL1, CXCL8, and CXCL10 in experi-
mental studies of lung inflammation [11-13]. Roflumi-
last is generally used for treatment of COPD patients
with reliable evidence of clinical trials [14,15]. Based
on these results, roflumilast was used in our study as a
positive control.
Stemona tuberosa has long been used as a therapeutic
herb in Korean and Chinese medicine for the treatment
of lung diseases. There have been some reports on the
antifungal or antibacterial effects of Stemona tuberosa
[16-18], however, there have been only a few studies on
its inhibitory effects on lung inflammation. It has also
been reported that Stemona tuberosa has a significant ef-
fect on components of the respiratory system such as
the larynx and the lungs [19,20]. In this study, we inves-
tigated the effect of Stemona tuberosa on lung inflam-
mation via a subacute CS-induced mouse model. We
examined the therapeutic effects of ST in terms of both
immunological changes such as decreased cytokines
(TNF-α, IL-6) and chemokine (KC), and morphological
changes in the lung microenvironment.
Methods
Animals
Groups of five six-week-old female C57BL/6 mice were
purchased from Charles River Korea (Seoungnam, South
Korea). All mice were kept under pathogen-freeconditions with air conditioning and a 12 hr light/dark
cycle. In addition, all mice had free access to food and
water during the experiments. This experimental study
was approved by the Institutional Animal Care and Use
Board of Kyung Hee University (KHUASP (SE)-12-015).
Preparation of Stemona tuberosa and phytochemical
analysis
ST was purchased from Sun Ten (Sun Ten Pharmaceut-
ical Co., Ltd. Taiwan). According to the manufacturer’s
procedure, water extraction of Stemona tuberosa was
performed. At first, the Stemona tuberosa was water ex-
tracted at 100°C for 60 min. And then, the remains of
the herbs and impurities were separated from the ex-
tracted liquid as a filtration separation process. The
water extracts were then spray dried and corn starch
was added as an excipient to stabilize the concentrated
herbal products (final ratio of water extracts vs starch is
7:3, Batch No: 110410). After these procedures, the final
product of Stemona tuberosa extract (ST) was produced
in Sun Ten. ST was carefully measured to prepare the
necessary weights for each treatment group and then
dissolved in distilled water (DW) for 30 min at room
temperature.
Stemona tuberosa extract (ST) is one of the herbal
extracts in PM014, which are well-standardized herbal
formula and has been investigated for treating lung
diseases recently [21]. PM014 has been already ap-
proved for the Investigation New Drug (IND) applica-
tion from Ministry of Food and Drug Safety, Republic
of Korea (ID:20130030575) through quantitating standard
materials by high-performance liquid chromatography
(HPLC) analysis. Accordingly, ST can be considered as a
standardized plant extract.
For the phytochemical analysis of ST, HPLC was per-
formed. The ST was accurately weighed to 10.53 mg and
then dissolved in 2 ml of methanol. The sample was
treated with ultrasonic waves for 30 min, and the super-
natant of the sample was then filtered through a 0.45-μm
syringe filter. For the quantitative analysis of ST, tuberos-
temonine N, one of the known alkaloid constituents of ST,
was isolated from the ethyl acetate extract of ST by re-
peated column chromatography. HPLC analysis were con-
ducted using a Waters system (Waters Co., Milford, MA,
USA) with a 2424 ELS detector and a 1525 binary HPLC
pump. A Waters Millennium 32 System (Waters Co.,
Milford, MA, USA) was used for data acquisition and in-
tegration. The samples were analyzed by reverse phase
(C18) HPLC analysis (Agilent prep-C18 Scalar, 4.6 ×
250 mm i.d., 5 μm, flow rate: 0.5 ml/min) using a gradient
solvent system of acetonitrile containing 0.05% triethyla-
mine (A) and water (B) as follows: 40% A at 0–10 min,
40→ 50% A at 10–20 min, 50% A at 20–40 min, 50→
40% A at 40–50 min and 40% A at 50–60 min. The drift
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pressure of the nebulizing nitrogen gas. The ELSD gener-
ates a signal in direct proportion to the quantity of the an-
alyte present. Using this method, the concentration of
tuberostemonine N in ST was calculated to be 0.3 mg/g
(yield 0.03%) as described in (Figure 1).
High Performance Liquid Chromatography – electrospray
tandem mass spectrometry (HPLC-ESI-MS) analysis
The HPLC (High performance liquid chromatography)
system operated by Chromeleon (Thermo Fisher Scientific,
USA) and consisted of Dionex model P680 HPLC pump, a
ASI-100 Automated Sample injector and a UVD 340U.
The Brownlee Analytical C18 column (4.6 × 250 mm,
5 μm) was selected for the analysis. The monitoring wave-
length was set to 254 nm. The mobile phase was comprised
of acetonitrile with triethylamine (0.1%, solvent A) and
water (solvent B). All solvents were filtered through a
0.45m filter. The gradient program was 0–10 min, 40% of
solvent A; 10– 12 min, linear from 40 to 50% of solvent A;
12–28 min, 50% of solvent A; 28– 30 min, linear from 50
to 40% of solvent A, at a flow rate of 0.6 mL per min. The
injection volume was 10 μL.
AccuTOF® single-reflectron time-of-flight mass spec-
trometer was operated with Mass Center system version
1.3.7b (JEOL, USA) and was equipped with an ESI source
(Electrospray ionization, JEOL, USA). In the positive ion
mode, the atmospheric pressure interface potentials were
typically set to the following values: orifice 1 = 80 V andFigure 1 The HPLC analysis of the standard material to ST. Phytochem
section. Tuberostemonine N was utilized as an authentic standard (arrows)
calculated to be 0.3 mg/g (yield 0.03%). a) HPLC-ELSD analytical data of turing lens and orifice 2 = 10, 5 V, respectively. The ion
guide potential and detector voltage were set to 2000 V
and 2300 V, respectively. ESI parameters were set as fol-
lows: needle electrode = 2000 V, nitrogen gas was used
as a nebulizer, desolvating and their flow rate were1 and
3 L/min, desolvating chamber temperature = 250°C, ori-
fice 1 temperature = 80°C. Mass scale calibration was ac-
complished with Yokudelna (Koyo Science Co., LTD.,
Japan) for accurate mass measurements and calculations
of the elemental composition. MS acquisition was set
with a scan range of m/z 50 to 1500.
A mouse model of subacute CS-induced lung inflammation
and drug treatment
Female C57BL/6 mice were exposed to either fresh air
(as a control group) or CS generated by 3R4F Kentucky
Reference Cigarettes (University of Kentucky, Lexington,
KY). As the subacute CS-induced lung inflammation
mouse model used here was based on previous studies
[22,23], mice were exposed over their entire bodies to
the smoke of five cigarettes, four times per day with
30 min smoke-free intervals, on 6 days per week for
2 weeks. They were dosed with DW on days 0 and 1,
and DW or ST on days 2 to 5 and 7 to 12 as described
in (Figure 2). The mice were treated with 5 mg/kg dose
of roflumilast (Santa Cruz Biotechnology, Inc., CA,
USA) orally as a positive control on the same days as
ST, and different doses of ST (50, 100, and 200 mg/kg)
via oral injection 2 hr before exposure to CS. On day 13,ical analysis was performed by HPLC as described in the Methods
and found that the concentration of tuberostemonine N in ST was
berostemonine N, b) HPLC-ELSD analytical data of ST.
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for confirming this mouse model is successful and ana-
lyzing the results.
Analysis of bronchoalveolar lavage fluid (BALF)
BALF was collected by the infusion and extraction of
1 ml of ice cold phosphate buffered saline (PBS). This
procedure was repeated three times, and the lavages
were pooled. The recovered BALF (70–80%) was centri-
fuged at 1,300 rpm for 10 min. The cell pellets were re-
suspended in 1 ml PBS and adhered to glass slides using
cytocentrifugation. The total viable cell counts were
determined in a hemocytometer using the trypan blue
exclusion method. Differential counts of macrophages,
neutrophils, and lymphocytes were determined on
Diff-Quick-stained (Life Technologies, Auckland, New
Zealand) cytospin smears of BALF samples (5 × 105 /200 μl
cells) from individual mice. BALF samples were then
centrifuged and the supernatants were kept at −80°C.
The results are expressed as the total cell number × 104.
Assessment of protein, cytokines and chemokines in BALF
using Enzyme-Linked Immunosorbent Assay (ELISA)
Protein concentrations were determined using a BCA kit
(Pierce Biotechnology Inc., IL, USA). A total 25 μl of the
centrifuged BALF samples was placed into the micro-
plate well, and then 200 μl of the working reagent was
added to the each well. After incubation at 37°C for
30 min, the optical density was measured at 590 nm in a
microplate reader (SOFT max PRO, version 3.1 software,
Sunnyvale, CA, USA). The concentrations of cytokines
(TNF-α, IL-6) and the chemokine (KC) were measured
with a quantitative sandwich enzyme-linked immuno-
assay kit (BD, San Diego, CA, USA) following theFigure 2 Experimental design of subacute cigarette smoke-
induced lung inflammation mouse model. Female C57BL/6 mice
were exposed (whole body) to the smoke of five cigarettes, four
times per day with 30 min smoke-free intervals, on 6 days per week
for 2 weeks. Mice were orally treated with DW on days 0 and 1, and
DW, roflumilast (5 mg/kg), or ST (50, 100, and 200 mg/kg) on days 2
to 5, and 7 to 12. On day 13, mice were sacrificed to acquire BALF
and lung tissues for other analyses.manufacturer’s instructions. Microtiter plates (96-well,
Costar, Corning, NY, USA) were incubated overnight at
4°C with anti-mouse TNF-α, IL-6, and KC monoclonal
antibodies in coating buffer. The wells were then washed
with PBS containing 0.05% Tween-20 (Sigma-Aldrich
Co., St. Louis, MO, USA) and blocked with 5% FBS and
1% BSA in PBS. Subsequently, each well was loaded with
100 μl of BALF and incubated for 2 hr at room
temperature. The wells were then incubated with
peroxidase-labeled biotinylated anti-mouse TNF-α, IL-6,
and KC monoclonal secondary antibodies in assay diluents
for 1 h. Finally, the plates were treated with TMB substrate
solution (KPL, San Diego, CA, USA) for 30 min, and the
reaction was stopped by the addition TMB stop solution.
Optical density was measured at 450 nm in a microplate
reader (SOFT max PRO, version 3.1 software, Sunnyvale,
CA, USA). The detection limits for the TNF-α, IL-6, and
KC ELISAs were 1000 pg/ml each. The optical densities
for TNF-α, IL-6, and KC were each divided by the total
protein concentrations of the respective BALF samples for
standardization purposes.
Histological examination of lung tissues
The lung tissues were removed from the mice, and the
right, lower lobes of the lungs were removed for histo-
logical analysis. Four percent paraformaldehyde fixing
solution was infused into the lungs. The specimens were
dehydrated and embedded in paraffin. For histological
examination, 4-μm sections of embedded tissues were
cut on a rotary microtome, after which they were placed
on glass slides, deparaffinized, and stained sequentially
with hematoxylin and eosin (H&E). Images of lung tissue
sections stained with H&E were acquired with an Olympus
BX51 microscope (Olympus, Tokyo, Japan) under × 200
magnification. Five randomly selected sections of the
slides, cross-sections of lung parenchyma, were cap-
tured, digitized and evaluated using Image Pro-Plus 5.1
software (Media Cybernetics, Inc., Silver Spring, MD,
USA). Mean alveolar airspace (MAA), a quantitative as-
sessment of lung structure, was determined from the sum
of the alveolar airspace areas divided by the number of
identified alveoli. The bronchial epithelium was observed
with periodic acid Schiff (PAS)-stained sections.
Statistical analysis
Statistical analysis of the data was conducted using
Prism 5 software (GraphPad Software Inc., Irvine, CA,
USA). All values are presented as the means ± S.E.M.
(standard error of the mean). Differences between the
means of the control and the treatment samples were
determined by one-way ANOVA for multiple group
comparisons followed by Newman-Keuls post hoc com-
parisons. In all cases, p < 0.05 was considered to be sta-
tistically significant.
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Stemona tuberosa extract (ST) inhibits the increase of
inflammatory cells in BALF
Stemona granule was analyzed using HPLC-ESI-MS for
the analysis and identification of major components. As
shown in Table 1, characteristic components of Stemona
species including stemona alkaloids were identified by
the comparison of their retention order and molecular
weight with previous reports [24].
Stemona tuberosa extract (ST) inhibits the increase of
inflammatory cells in BALF
BALF was analyzed to evaluate how ST has a significant
effect on lung inflammation in a subacute CS-induced
mouse model. In previous studies, the number of total
inflammatory cells was significantly increased when mice
were exposed to CS for 2 weeks [23,25]. In our study,
CS caused a significant increase in the number of total
inflammatory cells compared with mice that were ex-
posed to fresh air only (Figure 3). On the other hand,
roflumilast and ST in all doses showed significant de-
crease in the number of total inflammatory cells in
BALF. It is safe to say that ST has an inhibitory effect on
the increase of inflammatory cells in BALF.
An analysis of differential BALF cell counts is also es-
sential to examining the anti-inflammatory effect of ST
(Figure 3). Macrophages, neutrophils, and lymphocytes
are well known to infiltrate from the alveoli to the bron-
choalveolar lavage in order to contribute to lung inflam-
mation that results from CS exposure [26]. The group of
mice exposed to CS (CS group) showed significant in-
creases in the number of macrophages, neutrophils, and
lymphocytes compared with group of mice that were ex-
posed to fresh air only as a negative control (AIR group).
Additionally, roflumilast and ST (50, 100, and 200 mg/kg)
inhibited the increase of neutrophils and lymphocytes in
BALF compared with the CS group. In detail, the num-
ber of macrophages was decreased to a lesser degree
than that of neutrophils and lymphocytes. In the previ-
ous study, roflumilast did not show the remarkable in-
hibitory effect on increased macrophages in BALF [13].
ST had the tendency to decrease the number of macro-
phages in BALF, but this reduction did not surpass thatTable 1 The observed and calculated mass numbers ofLC/ESI-
Peak No. Rt (min) Theoretical mass [M + H]+ Observed mass [M + H
1 3.073 406.22239 406.22642
2 5.658 338.19618 338.19668
3 15.040 392.24313 392.24367
4 17.402 376.24821 376.24806
5 19.311 390.22748 390.23615
6 25.729 376.24821 376.24755induced by roflumilast. ST also decreased the number of
neutrophils to a similar degree as did roflumilast. How-
ever, ST surprisingly had a significant effect on decreas-
ing the number of lymphocytes in a dose-dependent
manner, and this effect was more significant than that of
roflumilast.
Stemona tuberosa extract (ST) reduces the level of
proinflammatory mediators in BALF
ELISA was used to evaluate the differences in the ex-
pression of inflammatory mediators such as cytokines
(TNF-α, IL-6) and the chemokine, KC, between the
treatment groups. In previous studies, the secretion of
TNF-α and IL-6 into the BALF was shown to be activated
in response to CS via some types of inflammatory cells
[27-29]. KC, a chemokine which is also called chemokine
(C-X-C motif ) ligand 1 and growth-related oncogene α,
was found to be elevated in lung inflammation induced
by CS [30,31]. In this study, we identified that the levels
of both cytokines (TNF-α, IL-6) and KC were signifi-
cantly elevated in the CS group compared to the AIR
group (Figure 4).
Roflumilast, a positive control in this study, had inhibi-
tory effects on the increased cytokine (TNF-α, IL-6) and
chemokine (KC) secretion observed in our study (Figure 4).
Specifically, the levels of TNF-α and IL-6 in the group
of mice treated with roflumilast (ROFL group) were sig-
nificantly decreased compared with levels in the CS
group, but the level of KC only had the tendency to be
decreased, as was observed in previous studies [32].
In addition, ST-treated mice showed significantly de-
creased levels of TNF-α and IL-6 in all treated doses to
the same degree as that caused by roflumilast. These re-
markable changes in cytokine and chemokine levels
strongly demonstrate that ST reduces the level of proin-
flammatory mediators in BALF.
Stemona tuberosa extract (ST) disturbs the recruitment of
neutrophils in lung tissues
We previously found that CS induces an increase of
neutrophils in BALF through the assessment of differen-
tial cell counts, as described in the Methods section.
This recruitment could also be observed uponMSpeaks of Stemonae Radix granules








Figure 3 Total and differential cell counts in BALF. Exposure to cigarette smoke (CS) increased the numbers of total cells, macrophages,
neutrophils, and lymphocytes in BALF. In addition, ST significantly reduced the numbers of these inflammatory cells in BALF to a similar degree as
roflumilast. The numbers of cells in BALF were counted using a hemocytometer, and differential cell counts were performed on slides prepared
by cytocentrifugation at 250 rpm for 3 min followed by Diff-Quick staining. a) Count of total cell number, b) Count of macrophages, c) Count of
neutrophils, d) Count of lymphocytes. n = 5 in all groups. Data are shown as the mean ± S.E.M. Statistical analyses were conducted by one-way
ANOVA followed by Newman-Keuls Multiple Comparison test; ###p < 0.001, ##p < 0.01 vs. AIR, ***p < 0.001, **p < 0.01, *p < 0.05 vs. CS.
Figure 4 Measurement of TNF-α, IL-6, and KC levels in BALF by ELISA. BALF samples were collected as described in Figure 2. ST reduced the
level of cytokines (TNF-α, IL-6) and chemokine (KC) when measured with a quantitative sandwich enzyme-linked immunoassay (ELISA). a) TNF-α,
b) IL-6, c) KC. n = 5 in all groups. Data are shown as the mean ± S.E.M. Statistical analyses were conducted by one-way ANOVA followed by
Newman-Keuls Multiple Comparison test; ###p < 0.001, #p < 0.05 vs. AIR, ***p < 0.001, **p < 0.01, *p < 0.05 vs. CS.
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ported that neutrophils accumulate in the tissue to in-
duce the lung inflammation, a leading potential
mechanism of alveolar destruction in emphysema [33-35].
The accumulation of neutrophils around the bronchioles
of the small airways was shown in lung tissue sections
stained with H&E. This accumulation was reported to re-
sult from the circulating neutrophils that had marginated
into the pulmonary circulation and adhered to endothelial
cells in the alveolar wall before infiltrating into the alveolar
space [36,37]. In this study, it was revealed that neutro-
phils located in the peribronchial airway were predomin-
antly increased in the lung tissues of the CS groupFigure 5 Neutrophil recruitment and airspace enlargement in lung tis
hematoxylin and eosin (×200 magnification). ST disturbed the neutrophil a
(MAA), a morphometrical analysis, was assessed using Image Pro-Plus 5.1 so
are shown as the mean ± S.E.M. Statistical analyses were conducted by one
###p < 0.001 vs. AIR, ***p < 0.001 vs. CS.compared to the AIR group (Figure 5A). Additionally, the
lung morphology of mice treated with ST (50, 100, and
200 mg/kg) showed that ST disturbed the accumulation of
neutrophils throughout the peribronchial airway when
compared with that of mice that were only exposed to CS
without any treatment. The morphological appearance of
the ST group was similar to that of the ROFL group.
Stemona tuberosa extract (ST) decreases the airspace
enlargement as observed by morphometric analysis
Several investigations indicated that the exposure to CS
significantly induced the destruction of the alveolar wall
and airspace enlargement through lung inflammation,sue. a) The right lower lobes of mice were dissected and stained with
ccumulation in the peribronchial airway. b) Mean alveolar airspace
ftware as described in the Methods section. n = 5 in all groups. Data
-way ANOVA followed by Newman-Keuls Multiple Comparison test;
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MAA in lung tissue sections stained with H&E via mor-
phometric analysis, which is a quantitative assessment
used to measure the changes of airspace enlargement
[43,44]. Serious airspace enlargement in a subacute CS-
induced mouse model due to lung inflammation and al-
veolar wall destruction could be identified in our study
by comparing MAA levels between the AIR group and
the CS group (Figure 5B). Meanwhile, the oral adminis-
tration of roflumilast and all doses of ST significantly re-
duced the level of MAA. Specifically, the level of MAA
in each ST group decreased a little more than that in the
ROFL group, and ST had a dose-dependent effect on the
prevention of alveolar airspace enlargement, based on
this quantitative assessment.
Stemona tuberosa extract (ST) attenuates the epithelial
hyperplasia of the bronchioles
Many research articles have described that CS-induced
inflammatory cell infiltration, metaplasia of goblet cells,
and fibrosis result in the increased thickness of the bron-
chial epithelium [22,45-48]. However, even though mice
were exposed to CS chronically, the metaplasia of goblet
cells in the bronchial epithelium was hardly found, but
there were plentiful numbers of goblet cells in human
and guinea pig when exposed to CS. Accordingly, some
studies of the CS-induced lung inflammation mouse
model have only investigated the epithelial hyperplasia
of the bronchioles because of the difficulty in estimating
the number of goblet cells in the bronchial epithelium of
mice [49-51]. PAS stain method has been used to distin-
guish the epithelial thickness of bronchiole in other
studies [22,52]. In this mouse model of subacute CS-
induced lung inflammation, lung tissues of the CS groupFigure 6 Epithelial hyperplasia of the bronchioles. The right lower lobe
described in the Methods section (×400 magnification). In the cigarette smok
there was approximately a single layer of bronchial epithelium in the fresh airstained with PAS showed the epithelial hyperplasia of
the bronchioles, leading to the increased thickness of
bronchial epithelium compared with the AIR group
(Figure 6). The inhibition of epithelial hyperplasia of the
bronchioles was also observed in PAS-stained lung tis-
sues of the ST group, similar to those of the ROFL
group. Morphologically, more than two epithelial cells
were clustered and formed a thick layer of bronchial epi-
thelium in that of the CS group, but there was only a
single row of epithelial cells in the lung tissues of the ST
group.
Discussion
For thousands of years many drugs including natural
plants and chemical compounds have been investigated
to find effective treatments for lung diseases such as
bronchitis, asthma, and COPD. Particularly in Korean
and Chinese medicine, traditional medical doctors have
used therapeutic herbs to treat lung diseases according
to their traditional medical reference books such as
Huangdineijing and DonguiBogam. DonguiBogam was
published by the royal physician Jun Heo in the Joseon
Dynasty of Korea and designated as UNESCO's memory
of the world register in 2009 [53]. Under the contempor-
ary and social requirements, many researchers have made
an effort to demonstrate the therapeutic effects of the
herbs introduced in those literatures, and found some
therapeutic herbs such as Lilium lancifolium, Liriopis
tuber, Coscinium fenestratum, and Prunus armeniaca
have been proved to have an interesting effect on lung
diseases [53-56]. ST has also shown promise as an al-
ternative treatment for lung diseases [19,20].
To evaluate the degree of inhibition of lung inflamma-
tion, many researchers prefer the CS-induced mouses of mice were dissected and stained with periodic acid Schiff (PAS) as
e (CS) group, there was a multi-layer of bronchial epithelium, whereas
(AIR), roflumilast (ROFL), and ST groups.
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This model is induced by the same insult as observed in
humans and produces emphysema, airway remodeling,
and physiological alterations similar to humans [51]. In
our study, the effect of Stemona tuberosa on lung inflam-
mation was investigated using a CS-induced mouse
model, which is one of the models that is most similar
to lung diseases including COPD. Two weeks of cigarette
smoke exposure in this model was enough to induce al-
veolar wall destruction and airspace enlargement, based
on previous studies [21,53-57].
CS, which nearly accounts for 80-90% of COPD cases
in the United States, induces pathobiological processes
in the respiratory system [58]. A plenty of results from
other studies likely demonstrate that airspace enlarge-
ment and neutrophil accumulation around the peribron-
chial airway in our histologic analysis have a significant
relationship with the increased macrophages and neutro-
phils found in BALF after CS exposure [59-63]. However,
more detailed studies should be performed to identify
whether the inhibitory effect of ST on lung inflammation
involves these mechanisms.
In our research, we also investigated the changes in
lymphocyte levels as well as those of macrophages and
neutrophils because lymphocytes are another important
factor in lung inflammation related to respiratory dis-
eases such as asthma and COPD. In asthma, the CD4+ T
cells, a type of lymphocyte, are the crucial mediators of
a Th2 type immune response in the bronchial airway,
whereas the CD8+ T cells are more important in COPD
[64,65]. The greater the CS exposure, the larger the popu-
lation of total T cells, including CD3+, CD4+, CD8+, and
γδ T cells in the alveolar wall, in the previous study. Of all
these T cells, CD8+ T cells were the most predominant cell
type found in bronchial airways in smokers with emphy-
sema. These results suggested that CD8+ T cells induced
structural cell apoptosis in the lung [66]. A recent study
also demonstrated that CD3+ T cells could be another
pathogenic cell in mice exposed to CS, leading to neu-
trophil accumulation, enhanced levels of cytokines and
chemokines, structural cell apoptosis of the alveoli, and
airspace enlargement [67]. In our research, the in-
creased level of lymphocytes could also be associated
with airspace enlargement observed via morphometric
analysis. In conclusion, several types of lymphocytes
such as CD3+, CD4+, and CD8+ T may be candidate tar-
gets of ST, which would explain the finding of decreased
lymphocyte levels in BALF and reduced airspace en-
largement in the ST groups, compared with those in the
CS group.
In our research, we investigated the alteration of the
cytokines (TNF-α, IL-6) and the chemokine (KC) in
BALF by ELISA to assess the inhibitory effect of ST.
These cytokines and the chemokine have been generallyused in CS-induced mouse model, especially for COPD
in previous studies [21,68,69]. Some studies have reported
that a variety of cytokines and chemokines in BALF are
involved with the lung inflammation induced by CS and
are also increased in COPD patients [70]. Previous stud-
ies reported that TNF-α overexpression can be observed
in the lung tissue of normal mice exposed to CS, whereas
TNF-α receptor knockout mice were protected from the
severe inflammation caused by CS. Furthermore, in-
creased TNF-α levels stimulated the MMP synthesis of
alveolar macrophages, resulting in alveolar wall destruc-
tion and airspace enlargement [71,72]. Meanwhile, IL-6,
a cytokine released by macrophages, lymphocytes, and
endothelial cells, is another target to treat lung inflam-
mation leading to COPD. IL-6 is also known to contrib-
ute to impaired endothelial cell function, which leads to
enlarged alveolar airspaces [73,74]. ST could be a poten-
tial alternative to existing treatments that inhibit TNF-α
and IL-6 because we have shown in this study that ST
can attenuate TNF-α and IL-6 levels.
We investigated the effect of ST on lung inflammation
through total cell counts, differential cell counts, changes
in the level of the cytokines (TNF-α, IL-6) and the chemo-
kine (KC) by ELISA, and the morphological analysis of
lung tissues stained with H&E and PAS. Our goal is to
identify a new therapeutic herb for lung diseases such as
COPD based on other studies of the respiratory effects of
ST [19]. The respiratory effects of ST, however, were dem-
onstrated for symptoms such as antitussive and respira-
tory depressant effects, so our study tried to minutely
examine the immunological changes associated with these
effects. In summary, ST inhibited the increase of several
inflammatory cells such as macrophages, neutrophils, and
lymphocytes, and decreased the levels of proinflammatory
cytokines such as TNF-α and IL-6 and the chemokine,
KC. This immunological downregulation in lung tissue
may lead to reduced alveolar wall destruction, airspace en-
largement, and epithelial hyperplasia of the bronchioles,
as demonstrated by morphological analysis and MAA
measurements. Although inflammatory cells and media-
tors in BALF and MAA in lung tissue that we investigated
were significantly reduced in all doses of ST treatment
group rather than CS exposure group, we could not find
the differences among the three doses of ST except dose-
dependent decrease in the number of lymphocytes. Mean-
while, it is possible that 50 mg/kg of ST, the minimum
dose in our study, already reached the maximal effect on
lung inflammation in this model.
We could find a few limitations in this mice model to
evaluate the effect of ST. First, we had a difficulty in
finding the increased number of goblet cells or fibrotic
changes in the bronchial epithelium of CS group. To
evaluate the effect of ST with these characteristics, re-
searchers should perform this experimental study with
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this study was designed to examine the effects of CS ex-
posure in regard to inflammation only. Recent studies,
however, examine the effects of CS exposure in the aspect
of DNA damage as well as inflammation [76]. Further-
more, one study researched the effect of a therapeutic
herb, Zataria multiflora, on systemic inflammation of
experimental animal model of COPD. They used biochem-
ical parameters such as measurement of malondialdehye
and differential cell count in the blood sample [77]. Ac-
cording to these recent studies, other biomarkers that
can evaluate the effect of ST on targeting the treatment
of COPD should be performed for the further studies.
Previous studies have been conducted to discover the
components of ST such as neotuberostemonine, tuberos-
temonine, croomine, and stemoninine, as well as their
chemical structures, effects, and ethnopharmacological
uses [20,24,78]. In one of these studies, tuberostemonine
was proven to have an inhibitory effect on the neuromus-
cular junction [79]. Additionally, some Stemona species
other than ST have been continuously used as therapeutic
agents in Korean and Chinese medicine. For instance, Ste-
mona japonica and its alkaloids have insecticidal and anti-
fungal effects [18,80]. Stemona sessilifolia and its alkaloids
also have acetylcholinesterase inhibitory activity as well
as antibacterial and antitussive effects [17,81,82]. To ex-
tend a helping hand to patients with lung diseases such as
COPD, the effects of ST should be compared with these
similar species through the pathobiological investigation
of both experimental and clinical trials. Also, further re-
searches should be performed to discover which phyto-
constituents of ST have crucial inhibitory effect on lung
inflammation. With the help of additional studies, ST may
represent a potential alternative for existing drugs,
such as roflumilast, that are used to treat lung diseases
and have some side effects. Roflumilast, an oral
phosphodiesterase-4 (PDE) inhibitor, can improve lung
diseases such as COPD, but side effects have been re-
ported. The most common side effects include diar-
rhea, nausea, and headache [83]. ST could be a good
therapeutic agent for lung diseases and may even be a
better treatment than roflumilast. However, it is neces-
sary that the elaborate mechanisms of ST be precisely
discovered by additional experiments, and it should be
produced in farms of good agricultural practice (GAP)
and pharmaceutical companies of good manufacturing
practice (GMP) [19]. In conclusion, based on our results
that ST has significant inhibitory effects in a mouse model
of subacute CS-induced lung inflammation, more studies
should be performed to determine the critical targets of
ST, whether ST has any side effects, and how ST can be
manufactured with the best effectiveness and efficacy for
the purpose of its pharmacological development and clin-
ical use.Conclusions
We found the significant changes of lung inflammation
in a subacute cigarette smoke-induced mouse model.
With this mouse model, we discovered that ST treatment
decreased a variety of inflammatory cells of the lung such
as macrophages, neutrophils, and lymphocytes and reduced
the level of cytokines (TNF-α, IL-6) and a chemokine (KC)
induced by CS exposure. It also attenuated the airspace en-
largement and epithelial hyperplasia of bronchioles in lung
tissues obtained from the mouse model of subacute CS-
induced lung inflammation. These results strongly suggest
that ST may be a new valuable therapeutic agent for the
treatment of lung diseases such as COPD.
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